ArticleParasites & vectors2015
Development of patent Litomosoides sigmodontis infections in semi-susceptible C57BL/6 mice in the absence of adaptive immune responses.
Article in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Development of Dirofilaria immitis adult worms in NSG mice, detection of parasite-derived microRNA and comparative analysis of laboratory isolates.Scientific reports · 2026Article
- Host environment shapes filarial parasite fitness and Wolbachia endosymbionts dynamics.PLoS pathogens · 2025Article
- Differences of in vitro immune responses between patent and pre-patent Litomosoides sigmodontis-infected mice are independent of the filarial antigenic stimulus used.Parasitology research · 2024Article
- Comparative development of human filariaeFrontiers in tropical diseases · 2024Article
- Potential of Nucleic Acid Receptor Ligands to Improve Vaccination Efficacy against the Filarial NematodeVaccines · 2023Article
- T helper 2 cells control monocyte to tissue-resident macrophage differentiation during nematode infection of the pleural cavity.Immunity · 2023Article
- Filariasis research - from basic research to drug development and novel diagnostics, over a decade of research at the Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany.Frontiers in tropical diseases · 2023Article
- Dirofilariasis mouse models for heartworm preclinical research.Frontiers in microbiology · 2023Article
- NKp46Frontiers in immunology · 2022Article
- Unbalanced Arginine pathway and altered maturation of pleural macrophages in Th2-deficient mice duringFrontiers in immunology · 2022Article
- ILC2s Control Microfilaremia DuringFrontiers in immunology · 2022Article
- Human filariasis-contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model.Parasitology research · 2021Review
- Adoptive Transfer of Immune Cells Into RAG2IL-2Rγ-Deficient Mice DuringFrontiers in immunology · 2021Article
- The immune response of inbred laboratory mice to Litomosoides sigmodontis: A route to discovery in myeloid cell biology.Parasite immunology · 2020Review
- Comparison of immune responses to Loa loa stage-specific antigen extracts in Loa loa-exposed BALB/c mice upon clearance of infection.Parasites & vectors · 2020Article
- Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.Journal of medicinal chemistry · 2019Article
- The central adaptor molecule TRIF influences L. sigmodontis worm development.Parasitology research · 2019Article
- Absence of IL-17A in Litomosoides sigmodontis-infected mice influences worm development and drives elevated filarial-specific IFN-γ.Parasitology research · 2018Article
- Chronic helminth infection burden differentially affects haematopoietic cell development while ageing selectively impairs adaptive responses to infection.Scientific reports · 2018Article
- NOD2 dependent neutrophil recruitment is required for early protective immune responses against infectious Litomosoides sigmodontis L3 larvae.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the most advantageous research aspects of the murine model of filariasis, Litomosoides sigmodontis, is the availability of mouse strains with varying susceptibility to the nematode infection. In C57BL/6 mice, L. sigmodontis worms are largely eliminated in this strain by day 40 post-infection and never produce their offspring, microfilariae (Mf). This provides a unique opportunity to decipher potential immune pathways that are required by filariae to achieve a successful infection. In this study we tracked worm development and patency, the production of microfilariae and thus the transmission life-stage, in Rag2IL-2Rγ(-/-) mice which are deficient in T, B and NK cell populations.
findingsAlthough worm burden was comparable between wildtype (WT) and Rag2IL-2Rγ(-/-) mice on d30, by day 72 post-infection, parasites in Rag2IL-2Rγ(-/-) mice were still in abundance, freely motile and all mice presented high quantities of Mf both at the site of infection, the thoracic cavity (TC), and in peripheral blood. Levels of cytokine (IL-4, IL-6, TNFα) and chemokine (MIP-2, RANTES, Eotaxin) parameters were generally low in the TC of infected Rag2IL-2Rγ(-/-)mice at both time-points. The frequency of neutrophils however was higher in Rag2IL-2Rγ(-/-)mice whereas eosinophils and macrophage populations, including alternatively activated macrophages, were elevated in WT controls.
conclusionOur data highlight that adaptive immune responses prevent the development of patent L. sigmodontis infections in semi-susceptible C57BL/6 mice and suggest that induction of such responses may offer a strategy to prevent transmission of human filariasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.